HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reaffirmed a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and increased the price target from $24 to $28, indicating a positive outlook on the company's stock.
December 15, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics' stock rating has been maintained as Buy by HC Wainwright & Co., with the price target raised from $24 to $28, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100